|
|
|
|
Halozyme Therapeutics and Baxter Release Results from the INFUSE-LR Study
Conditions Therapies Products Services About Baxter Baxter Worldwide > United States Training and Education Sustainability Contact Us - << Back to News Releases 2008 Archives 2007 Archives 2006 Archives 2005 Archives 2004 Archives 2003 Archives 2002 Archives 2001 Archives News Release Home > About Baxter > News Room > News Releases >...
Warnings for the use of Hylenex consist of...
|
|
|
Halozyme and Baxter Announce Availability of Hylenex
Conditions Therapies Products Services About Baxter Baxter Worldwide > United States Training and Education Sustainability Contact Us - << Back to News Releases 2008 Archives 2007 Archives 2006 Archives 2005 Archives 2004 Archives 2003 Archives 2002 Archives 2001 Archives News Release Home > About Baxter > News Room > News Releases >...
- About Hylenex - Hylenex recombinant ...
|
|
|
Halozyme And Baxter Expand Global HYLENEX Collaboration
Conditions Therapies Products Services About Baxter Baxter Worldwide > United States Training and Education Sustainability Contact Us - << Back to News Releases 2008 Archives 2007 Archives 2006 Archives 2005 Archives 2004 Archives 2003 Archives 2002 Archives 2001 Archives News Release Home > About Baxter > News Room > News Releases >...
- “HYLENEX recombinant is the first...
|
|
|
Halozyme Therapeutics and Baxter Present Promising Results for the Use of HYLENEX from the Infuse-Morphine Study
Conditions Therapies Products Services About Baxter Baxter Worldwide > United States Training and Education Sustainability Contact Us - << Back to News Releases 2008 Archives 2007 Archives 2006 Archives 2005 Archives 2004 Archives 2003 Archives 2002 Archives 2001 Archives News Release Home > About Baxter > News Room > News Releases >...
Morphine is a widely used drug for pain...
|
|
|
Baxter Introduces HYLENEX for use in Ophthalmic Surgery
Conditions Therapies Products Services About Baxter Baxter Worldwide > United States Training and Education Sustainability Contact Us - << Back to News Releases 2008 Archives 2007 Archives 2006 Archives 2005 Archives 2004 Archives 2003 Archives 2002 Archives 2001 Archives News Release Home > About Baxter > News Room > News Releases >...
- "The incorporation of animal-derived...
|
|
|
Baxter and Halozyme Announce Collaboration For Development Of Subcutaneous GAMMAGARD LIQUID™ Administration using
Conditions Therapies Products Services About Baxter Baxter Worldwide > United States Training and Education Sustainability Contact Us - << Back to News Releases 2008 Archives 2007 Archives 2006 Archives 2005 Archives 2004 Archives 2003 Archives 2002 Archives 2001 Archives News Release Home > About Baxter > News Room > News Releases >...
Upon regulatory approval, Halozyme will also...
|
|
|
Axis-Shield Enzymatic Homocysteine Assay
Home | Site Map | Contact Us Home About Us Laboratory Point Of Care Distribution Investor Relations --- View Our Lab.
Total homocysteine represents the sum of all Hcy species found in plasma and serum (free plus protein bound).
Hcy accumulates and is excreted into the blood when these reactions are impaired.
Other less severe genetic defects that lead to moderately elevated...
|
|
|
11744_pcepnu_nuvigil_master_14
NUVIGIL TM (armodafinil) Tablets [C-IV] Rx Only DESCRIPTION NUVIGIL TM (armodafinil) is a wakefulness-promoting agent for oral administration.
1.0% in the feces).
Evaluators were not given any specific guidance about the criteria they were to apply when rating patients.
In the NUVIGIL controlled studies, depression was also a reason for treatment discontinuation more often...
author: smelindo
duplicates:
http://www.anesta.com/newsroom/assets/Nuvigil_prescribing_information.pdf
|
|
|
11744_pcepnu_nuvigil_master_14 page 4
author: smelindo
duplicates:
http://www.anesta.com/newsroom/assets/Nuvigil_prescribing_information.pdf
|
|
|
11744_pcepnu_nuvigil_master_14 page 3
author: smelindo
duplicates:
http://www.anesta.com/newsroom/assets/Nuvigil_prescribing_information.pdf
|
|
|
231810_axis_homocyst_innm_alle
Instructions for use Mode d'emploi Gebrauchsanweisung Istruzioni per l'uso Instrucciones de uso Instrucoes da utilizacao Bruksanvisningen Brugervejledning Axis ® Homocysteine EIA FHCY100 Axis- Shield Diagnostics Ltd.
Dieses ist vergleichbar mit der Odds- Ratio bei einem Cholesterinanstieg um 0,5 mmol/ l (20 mg/ dl).
12, 13 Medikamente wie Methotrexat, Carbamazepin, ...
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle page 8
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle page 5
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle
Instructions for use Mode d'emploi Gebrauchsanweisung Istruzioni per l'uso Instrucciones de uso Instrucoes da utilizacao Bruksanvisningen Brugervejledning Axis ® Homocysteine EIA FHCY100 Axis- Shield Diagnostics Ltd.
9 Certain groupes de patients souffrant d'anemie et/ ou d'asthenie ont egalement presente des taux plasmatiques et seriques eleves d'Hcy.
12, 13 Des...
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle page 8
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle page 5
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle
Instructions for use Mode d'emploi Gebrauchsanweisung Istruzioni per l'uso Instrucciones de uso Instrucoes da utilizacao Bruksanvisningen Brugervejledning Axis ® Homocysteine EIA FHCY100 Axis- Shield Diagnostics Ltd.
10,11 Patients with chronic renal disease experience an excess morbidity and mortality due to arteriosclerotic CVD.
12, 13 Drugs such as methotrexate,...
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle page 8
author: Robert jans
|
|
|
231810_axis_homocyst_innm_alle page 5
author: Robert jans
|
|
|
http://www.axis-shield.com/assets/Homocysteine_EIA_Kit_Danish_version.pdf
Axis- Shield Diagnostics Ltd.
12, 13 Laegemidler saasom methotrexat, carbamazepin, phenytoin, dinitrogenoxid og penicillamin paavirker Hcy- metabolismen og kan medfore et forhojet homocysteinniveau.
Enzymatisk konvertering Hcy i proven konverteres til S- adenosyl- L- homocystein gennem SAH- hydrolase og overskydende adenosin (Ad).
Reagens D og H opbevares i morke...
|
|
|
http://www.axis-shield.com/assets/Homocysteine_EIA_Kit_Danish_version.pdf page 3
|
|
|
http://www.axis-shield.com/assets/Homocysteine_EIA_Kit_Danish_version.pdf page 2
|
|
|
BAX-003 PI Brochure v2
The FIRST and ONLY Human Recombinant Hyaluronidase Knowledge of the mechanisms involved in the disappearance of injected hyaluronidase is limited.
When no spreading factor is present, material injected subcutaneously spreads very slowly, but hyaluronidase causes rapid spreading, provided local interstitial pressure is adequate to furnish the necessary mechanical impulse.
|
|
|
BAX-003 PI Brochure v2 page 3
|
|
|
Microsoft Word - MLT-01724_Version1.0_Effective_Sept_12_2006.doc
1 HYLENEX recombinant (hyaluronidase human injection) Rx only DESCRIPTION HYLENEX recombinant is a purified preparation of the enzyme recombinant human hyaluronidase.
Hyaluronidase cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, some other acid mucopolysaccharides of the connective tissue.
INDICATIONS AND USAGE HYLENEX recombinant is indicated as an...
author: katzj1
|
